(Q34458339)

English

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

Katherine L Nathanson

8

object named as

Katherine L Nathanson

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

4

object named as

Rosemarie Mick

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

David L Bajor

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Xiaowei Xu

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Drew A Torigian

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Laura R Garcia

5

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lee P Richman

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Cindy Desmarais

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Lynn M Schuchter

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Michael Kalos

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Robert H Vonderheide

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

publication date

24 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Cancer Immunology Research

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1051-1058

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

CTLA4 blockade broadens the peripheral T-cell receptor repertoire

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Mitigating the toxic effects of anticancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Agonistic CD40 antibodies and cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

CD40-CD40 ligand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

6 July 2018

Ultra-sensitive detection of rare T cell clones.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

27 October 2018

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

27 October 2018

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

27 October 2018

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

27 October 2018

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221425

9 December 2018

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

https://pubmed.ncbi.nlm.nih.gov/25252722

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

1 reference

https://pubmed.ncbi.nlm.nih.gov/25252722

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/25252722

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/2326-6066.CIR-14-0154

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34458339&oldid=1956582404"